New Inhalation Formulations for Improved Delivery of Antimicrobials
| Reference number | |
| Coordinator | RISE Research Institutes of Sweden AB |
| Funding from Vinnova | SEK 4 137 500 |
| Project duration | November 2022 - December 2025 |
| Status | Ongoing |
| Venture | European partnership for antimicrobial resistance |
| Call | JPI AMR Joint Transnational Call 2022: Disrupting drug Resistance Using Innovative Design. |
Purpose and goal
To date no powerful inhalation formulations for the treatment of acute lower respiratory tract infections (LRTI) in hospitalized patients has been developed. Developing inhalation formulations is demanding and requires technologies to overcome a variety of hurdles and limitations. The goal is to develop innovative formulations to improve drug deposition at the sites of infection, enhance biofilm penetration, and increase the drug exposure in the relevant sites of infection by controlling drug release and clearance.
Expected results and effects
In this project we propose to utilize the latest advancements in formulation technologies to develop five distinct inhalation formulations of apramycin and competitively evaluate their pharmacokinetics, safety, and efficacy in an Acinetobacter baumannii animal infection model. The results from this case study will generate knowledge applicable for other antimicrobials as well.
Planned approach and implementation
** Denna text är maskinöversatt ** The project is coordinated by University of Zürich, and will be carried out in active collaboration between 7 project partners; RISE Research Institutes of Sweden AB (Sweden), Inhalation Sciences AB (Sweden), as well as CIDETEC (Spain), Fraunhofer ITEM (Germany), INSERM U1070 (France) and LIOS (Latvia).